drugset / Trial / NCT05948592
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
Timeline
- Start
- 2023-11-08
- Primary completion
- 2025-10-30
- Completion
- 2025-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TP-102 | Other / unclassified | 1 ml | Topical |
Indications
No indication recorded.